Cargando…

Correction to: Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway

Detalles Bibliográficos
Autores principales:	Wakabayashi, Grace, Lee, Yu-Ching, Luh, Frank, Kuo, Chun-Nan, Chang, Wei-Chiao, Yen, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927167/ https://www.ncbi.nlm.nih.gov/pubmed/31865911 http://dx.doi.org/10.1186/s12929-019-0601-2

Ejemplares similares

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
por: Wakabayashi, Grace, et al.
Publicado: (2019)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Correction: Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy
por: Liu, Can, et al.
Publicado: (2019)

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2022)

Author Correction: The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy
por: Wang, Gui-Zhen, et al.
Publicado: (2022)

Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
Publicado: (2022)

Correction: Hydronephrotic Urine in the Obstructed Kidney Promotes Urothelial Carcinoma Cell Proliferation, Migration, Invasion through the Activation of mTORC2-AKT and ERK Signaling Pathways
por: Chang, Chi-Hao, et al.
Publicado: (2015)

Correction: THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
Publicado: (2021)

Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

Correction: Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Publicado: (2021)

Cancer immunotherapies targeting the PD-1 signaling pathway
por: Iwai, Yoshiko, et al.
Publicado: (2017)

Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
por: Haikala, Heidi M., et al.
Publicado: (2019)

Correction: Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1- immunotherapy in colon cancer
Publicado: (2021)

Correction to: Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis
por: Wen, Liling, et al.
Publicado: (2022)

Correction to: Immunology of allergen immunotherapy
Publicado: (2023)

Correction: Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
Publicado: (2023)

Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
Publicado: (2023)

Correction To: Signaling pathways in obesity: mechanisms and therapeutic interventions
por: Wen, Xue, et al.
Publicado: (2022)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
Publicado: (2021)

Correction To: Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions
por: Qin, Chuan, et al.
Publicado: (2022)

Correction: Two roads for oncolytic immunotherapy development
Publicado: (2021)

Correction: PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
Publicado: (2022)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Publicado: (2021)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
Publicado: (2023)

Correction: The signal pathways and treatment of cytokine storm in COVID-19
por: Yang, Lan, et al.
Publicado: (2021)

Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models
por: Kuo, Chun-Ting, et al.
Publicado: (2020)

Correction: Immunotherapy for sarcomas: new frontiers and unveiled opportunities
Publicado: (2022)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Correction to: Toll-like receptor-mediated innate immunity against herpesviridae infection: a current perspective on viral infection signaling pathways
por: Zheng, Wenjin, et al.
Publicado: (2020)

Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
por: Guo, Zhiqiang, et al.
Publicado: (2017)

Correction: Comparative Reliability Studies and Analysis of Au, Pd-Coated Cu and Pd-Doped Cu Wire in Microelectronics Packaging
por: Chong Leong, Gan, et al.
Publicado: (2014)

Correction: Propentofylline Targets TROY, a Novel Microglial Signaling Pathway
por: Jacobs, Valerie L., et al.
Publicado: (2013)

Correction: Staining Pattern Classification of Antinuclear Autoantibodies Based on Block Segmentation in Indirect Immunofluorescence Images
por: Li, Jiaqian, et al.
Publicado: (2020)

Correction: Sirtuin 1 activation protects against early brain injury after experimental subarachnoid hemorrhage in rats
por: Zhang, Xiang-Sheng, et al.
Publicado: (2022)

Correction to: Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
por: Hao, Zhaonian, et al.
Publicado: (2022)

Correction to: Immunotherapy in prostate cancer: new horizon of hurdles and hopes
por: Tsaur, Igor, et al.
Publicado: (2021)

Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
por: Kawakubo, Kazumichi, et al.
Publicado: (2022)

Correction: Determinants of physical activity: A path model based on an ecological model of active living
por: Yen, Hsin-Yen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_63f5rk4fr4eshqfglq9th83qes